Stock Futures Drop, Treasury Yields Soar After Trump Threatens New Tariffs Over Greenland; Gold, Silver Hit Fresh All-Time Highs

Fastenal Stock Drops After Q4 Sales, Operating Income Margin Slightly Miss Estimates

FROM 15 minutes ago

Shares of Fastenal (FAST) sank 6.5% in premarket trading after the industrial distributor reported fiscal 2025 fourth-quarter net sales and operating income margin that narrowly missed analysts’ estimates.

The Winona, Minn.-based firm, which bills itself as “a leader in the wholesale distribution of industrial and construction supplies,” posted net sales that rose 11% year-over-year to just below $2.03 billion and operating margin of 19.0%. Analysts surveyed by Visible Alpha had expected just above $2.03 billion and 19.4%, respectively.

Fastenal’s profit of $0.26 per share matched consensus expectations.

The company said that “broader market conditions remain mixed, with ongoing challenges in industrial production.” 

Fastenal shares entered Tuesday having risen about 15% over the past year.

Trump Is Set to Unveil Big Plans Addressing Housing Affordability This Week. Here’s What We Know

FROM 59 minutes ago

Housing affordability has been a problem for the U.S. economy in recent years, and President Donald Trump is set to roll out what he describes as a series of “aggressive” reforms for the housing market this week.

Trump has said he will use his Wednesday speech at the World Economic Forum annual meeting in Davos, Switzerland, to lay out his ideas for the housing market. Trump and his advisors have signaled that the plans could have big implications for mortgages and how Americans buy homes.

Here’s what we know about the plan so far.

Read the full article here.

–Terry Lane

RAPT Therapeutics Stock Skyrockets as GSK Buys Biopharmaceutical Firm for $2.2B 

FROM 1 hr 19 min ago

Tuesday is looking like it’ll be a rough day for stocks. That does not appear to be the case for RAPT Therapeutics (RAPT) shareholders.

RAPT Therapeutics shares added nearly two-thirds of their value in premarket trading after drug giant GSK (GSK) said it had agreed to purchase the California-based biopharmaceutical firm for roughly $2.2 billion in stock.

GSK will pay RAPT Therapeutics shareholders $58.00 per share at closing—a 65% premium to Friday’s closing price of $35.10—and said its upfront investment is about $1.9 billion.

The deal, which is expected to close in the first quarter of 2026, would give GSK global rights to experimental food-allergy drug ozureprubart, excluding mainland China, Macau, Taiwan and Hong Kong.

“Food allergies cause severe health impacts to patients with existing treatment requiring injections as frequently as every 2 weeks,” GSK Chief Scientific Officer Tony Wood said. “Ozureprubart offers the opportunity to bring sustained protection to patients with dosing every 12 weeks, and is consistent with our approach to acquire assets that address validated targets and where there is clear unmet medical need.”

RAPT Therapeutics shares entered Tuesday up roughly 265% over the past year.

Stock Futures Dive After Trump Threatens New Tariffs Over Greenland

FROM 2 hr 5 min ago

Futures contracts connected to the Dow Jones Industrial Average pointed down 1.3%.

S&P 500 futures pointed down 1.6%.

Nasdaq 100 futures sank 1.9%.